首页 > 市场调查报告书 > 製药

再生医学

诱导性多功能干细胞细胞（iPS细胞）生产市场规模、份额和成长分析（按製程、工作流程、产品、应用、最终用途和地区划分）－产业预测，2026-2033年

市场调查报告书

商品编码

1898347

诱导性多功能干细胞细胞（iPS细胞）生产市场规模、份额和成长分析（按製程、工作流程、产品、应用、最终用途和地区划分）－产业预测，2026-2033年

Induced Pluripotent Stem Cells Production Market Size, Share, and Growth Analysis, By Process (Manual, Automated), By Workflow (Reprogramming, Cell Culture), By Product, By Application, By End-Use, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月19日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计到 2024 年，iPS 细胞（诱导性多功能干细胞）生产市场规模将达到 16.8 亿美元，到 2025 年将增长至 18.4 亿美元，到 2033 年将增长至 38.3 亿美元，在预测期（2026-2033 年）内复合年增长率为 9.6%。

在再生医学和细胞治疗领域，全球诱导多功能细胞（iPS细胞）生产市场正经历显着的成长和创新。 iPS细胞源自成人细胞，经重编程为多功能细胞，在个人化治疗和疾病建模方面具有巨大的潜力。推动这一市场发展的因素是人们对iPS细胞应用的认识不断加深，涵盖从药物研发到多种疾病治疗的各个方面。研究人员和生物技术公司正在探索创新方法，以提高iPS细胞的生产效率，并确保其扩充性和成本效益。学术界、产业界和医疗机构之间的合作正在推动该领域的进步。此外，严格的法规结构和伦理考量对于规范iPS细胞生产至关重要，凸显了标准化方法和安全通讯协定的必要性。这些因素共同促成了市场的持续扩张和治疗方法的突破性进展。

iPS细胞生产市场驱动因素

全球诱导多能干细胞（iPS细胞）生产市场的主要驱动力是再生医学领域的持续进步。 iPS细胞在为多种疾病开发个人化、有效的治疗方法方面具有巨大潜力，这促使人们加大对研发的投入。这些创新不仅拓展了iPS细胞的应用范围，也带来了突破性的治疗方案，吸引了製药公司和医疗机构的资金筹措。因此，该领域的持续发展在推动市场成长和拓展新治疗方法及新技术的机会方面发挥关键作用。

限制iPS细胞生产市场的因素

阻碍全球诱导多能干细胞（iPSC）生产市场发展的关键因素之一是各种伦理和监管方面的挑战。围绕人源材料的伦理问题以及iPSC技术被滥用的风险，导致多个地区实施了严格的监管措施。这些障碍阻碍了研究活动，增加了合规成本，并加剧了市场的不确定性，最终影响了iPSC的应用和商业化进程。在相关人员应对这些复杂挑战的过程中，整个iPSC市场的成长和发展可能会受到阻碍，导致创新和应用进程的延误。

iPS细胞生产市场趋势

诱导性多功能干细胞细胞（iPS细胞）生产市场正经历显着的成长趋势，这主要得益于iPS细胞技术在疾病建模领域日益广泛的应用。研究人员和製药公司正越来越多地利用iPS细胞来建构疾病特异性细胞株，从而能够以更精准、更个人化的方式模拟多种疾病，包括遗传性疾病、神经退化性疾病疾病和心血管疾病。这项策略转变不仅加速了药物发现和研发进程，也提高了标靶有效治疗策略的可行性。随着精准医疗日益受到关注，对iPS细胞技术的需求必将重塑未来生物医学研究和治疗的模式。

FUJIFILM Cellular Dynamics（USA）
Astellas Pharma（Japan）
Thermo Fisher Scientific（USA）
Takara Bio（Japan）
Lonza Group（Switzerland）
Merck KGaA（Germany）
ReproCELL（Japan）
STEMCELL Technologies（Canada）
Fate Therapeutics（USA）
Cynata Therapeutics（Australia）
Axol Bioscience（UK）
Ncardia（Belgium）
Pluricell Biotech（Brazil）
Evotec（Germany）
BioTime（USA）
Cellular Engineering Technologies（USA）
StemoniX（USA）
BrainXell（USA）
EMD Millipore（USA）
R&D Systems（USA）

结论与建议

简介目录

Product Code: SQMIG35H2225

Induced Pluripotent Stem Cells Production Market size was valued at USD 1.68 Billion in 2024 and is poised to grow from USD 1.84 Billion in 2025 to USD 3.83 Billion by 2033, growing at a CAGR of 9.6% during the forecast period (2026-2033).

The global market for induced pluripotent stem cell (iPSC) production is experiencing significant growth and innovation within the field of regenerative medicine and cellular therapy. iPSCs, derived from adult cells and reprogrammed to a pluripotent state, offer immense potential for personalized treatments and disease modeling. This market is fueled by an increasing understanding of iPSCs' applications, which range from drug discovery to treating various medical conditions. Researchers and biotechnology firms are pursuing innovative approaches to enhance iPSC production efficiency, ensuring both scalability and cost-effectiveness. Partnerships between academia, industry, and healthcare organizations are driving progress in the sector. Additionally, stringent regulatory frameworks and ethical considerations are crucial in shaping iPSC production, highlighting the need for standardized practices and safety protocols, positioning the market for continued expansion and groundbreaking therapeutic advancements.

Top-down and bottom-up approaches were used to estimate and validate the size of the Induced Pluripotent Stem Cells Production market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Induced Pluripotent Stem Cells Production Market Segments Analysis

Global Induced Pluripotent Stem Cells Production Market is segmented by Process, Workflow, Product, Application, End-Use and region. Based on Process, the market is segmented into Manual and Automated. Based on Workflow, the market is segmented into Reprogramming and Cell Culture. Based on Product, the market is segmented into Consumables & Kits, Instruments and Services. Based on Application, the market is segmented into Drug Development & Discovery, Regenerative Medicine, Toxicology Studies, Disease Modeling and Others. Based on End-Use, the market is segmented into Academic & Research Institutes, Biotechnology & Pharmaceutical Companies and Hospitals & Clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Induced Pluripotent Stem Cells Production Market

A significant driver of the global induced pluripotent stem cells (iPSC) production market is the ongoing advancements in regenerative medicine. IPSCs offer tremendous potential for creating personalized and effective treatments for a wide range of medical conditions, which in turn stimulates substantial investments in research and development. These innovations not only broaden the applications of iPSCs but also introduce groundbreaking therapeutic solutions, thereby attracting funding from pharmaceutical companies and healthcare institutions. As such, the continuous evolution in this field plays a crucial role in propelling market growth and expanding opportunities for new therapies and technologies.

Restraints in the Induced Pluripotent Stem Cells Production Market

One significant factor hindering the global induced pluripotent stem cells (iPSC) production market is the array of ethical and regulatory challenges present. The ethical implications surrounding human-derived materials and the risk of misuse of iPSC technology have led to the implementation of stringent regulations in various regions. These obstacles can impede research initiatives, increase compliance costs, and foster market uncertainty, ultimately affecting the speed at which iPSCs are adopted and commercialized. As stakeholders navigate these complexities, the overall growth and development of the iPSC market may be adversely impacted, leading to potential delays in innovation and application.

Market Trends of the Induced Pluripotent Stem Cells Production Market

The Induced Pluripotent Stem Cells (iPSC) production market is experiencing a significant trend driven by the growing integration of iPSC technology in disease modeling. Researchers and pharmaceutical companies are increasingly utilizing iPSCs to generate disease-specific cell lines, facilitating a more accurate and personalized approach to modeling various illnesses, including genetic disorders, neurodegenerative diseases, and cardiovascular conditions. This strategic shift not only accelerates drug discovery and development processes but also enhances the potential for targeted and effective therapeutic strategies. As precision medicine continues to gain traction, the demand for iPSC technology is set to reshape the future landscape of biomedical research and treatment.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Case Studies
Regulatory Landscape

Global Induced Pluripotent Stem Cells Production Market Size by Process & CAGR (2026-2033)

Market Overview
Manual
Automated

Global Induced Pluripotent Stem Cells Production Market Size by Workflow & CAGR (2026-2033)

Market Overview
Reprogramming
Cell Culture

Global Induced Pluripotent Stem Cells Production Market Size by Product & CAGR (2026-2033)

Market Overview
Consumables & Kits
Instruments
Services

Global Induced Pluripotent Stem Cells Production Market Size by Application & CAGR (2026-2033)

Market Overview
Drug Development & Discovery
Regenerative Medicine
Toxicology Studies
Disease Modeling
Others

Global Induced Pluripotent Stem Cells Production Market Size by End-Use & CAGR (2026-2033)

Market Overview
Academic & Research Institutes
Biotechnology & Pharmaceutical Companies
Hospitals & Clinics

Global Induced Pluripotent Stem Cells Production Market Size & CAGR (2026-2033)

North America (Process, Workflow, Product, Application, End-Use)
- US
- Canada
Europe (Process, Workflow, Product, Application, End-Use)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Process, Workflow, Product, Application, End-Use)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Process, Workflow, Product, Application, End-Use)
- Brazil
- Rest of Latin America
Middle East & Africa (Process, Workflow, Product, Application, End-Use)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

FUJIFILM Cellular Dynamics (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Astellas Pharma (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takara Bio (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lonza Group (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ReproCELL (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
STEMCELL Technologies (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fate Therapeutics (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cynata Therapeutics (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Axol Bioscience (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ncardia (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pluricell Biotech (Brazil)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Evotec (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioTime (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cellular Engineering Technologies (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
StemoniX (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BrainXell (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
EMD Millipore (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
R&D Systems (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments